FDA Approves Teva’s Cancer Drug

Bendeka now approved for treating cancer patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Teva's headquarters in Jerusalem.
Bloomberg

REUTERS - Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.

The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.

Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, is responsible for all U.S. commercial activities for Bendeka.